Randomized Phase III SIERRA Trial of

• Tác giả: Camille Abboud, Sunil Abhyankar, Zaid Al-Kadhimi, George Chen, Hannah Choe, Rachel Cook, Avinash Desai, James Foran, Sergio Giralt, Boglarka Gyurkocza, Elaina Haeuber, Parameswaran Hari, Katarzyna Jamieson, Partow Kebriaei, Nebu Koshy, Karilyn Larkin, Arjun Datt Law, Hillard M Lazarus, Moshe Y Levy, Mark R Litzow, James MacDougall, Kathleen McNamara, Pashna Munshi, Akash Nahar, Rajneesh Nath, Johnnie J Orozco, John M Pagel, Neeta Pandit-Taskar, Vijay Reddy, Scott D Rowley, Mitchell Sabloff, Brenda M Sandmaier, Michael Schuster, Stuart Seropian, Margarida Silverman, Jennifer Spross, Patrick Stiff, Benjamin Tomlinson, Koen Van Besien, Madhuri Vusirikala
• Ngôn ngữ: eng
• Ký hiệu phân loại: 373.236 Lower level
• Thông tin xuất bản: United States : Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2025
• Bộ sưu tập: NCBI
• ID: 699833

Tóm tắt

PURPOSE: Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate METHODS: SIERRA (ClinicalTrials.gov identifier: NCT02665065) was a phase III open-label trial. Patients age ≥55 years with active RR AML were randomly assigned 1:1 to either an RESULTS: The ITT population included 153 patients ( CONCLUSION: The